SCHEMBL1158733

SCHEMBL1158733

CC(C)(C)Nc1nc(Nc2cc(C(C)(C)C(N)=O)ccn2)cc2ccn(CCO)c(=O)c12

nearest known ligand 0.40

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SYK P43405 12/20 0.40
MASTL Q96GX5 3/20 0.31
CCNA2 P20248 1/20 0.30
CDK2 P24941 1/20 0.30
TTK P33981 1/20 0.30
RPS27 P42677 1/20 0.30
MAPK8 P45983 1/20 0.30
MAP3K12 Q12852 1/20 0.30
KIT P10721 1/20 0.30
FLT3 P36888 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158681 0.92 SYK (0.39) SYKMASTLMAP3K12
SCHEMBL1158537 0.90 SYK (0.42) SYKMASTLMAP3K12KITFLT3
SCHEMBL1159250 0.90 SYK (0.41) SYKMASTLMAP3K12
SCHEMBL1158643 0.89 SYK (0.41) SYKMASTLMAP3K12
SCHEMBL1159228 0.89 SYK (0.40) SYKMASTLMAP3K12KITFLT3
SCHEMBL6519251 0.89 SYK (0.40) SYKMASTLMAP3K12
SCHEMBL1159637 0.89 SYK (0.41) SYKMAP3K12
SCHEMBL1158718 0.88 SYK (0.41) SYKCCNA2CDK2TTKRPS27
SCHEMBL1159717 0.87 SYK (0.39) SYKMASTLMAP3K12KITFLT3
SCHEMBL1158692 0.87 SYK (0.39) SYKMASTL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US claimed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO claimed
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN SYK 1/4885MASTL 443/4885CCNA2 3434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.